SITC Annual Meeting 2026: key results and trends

What the 1,128 abstracts at SITC Annual Meeting 2026 reported, drug by drug: the readouts that stood out and the targets and modalities that dominated, and how this edition compares with earlier years.

abstracts
1,128
12% fewer than 2025
drug-linked abstracts
647
companies
272
from Phase 3 studies
7

Drug-linked abstracts by phase

  • Phase 1 76
  • Phase 1/2 31
  • Phase 2 41
  • Phase 2/3 2
  • Phase 3 7

Key results

Quotes are taken verbatim from each abstract's results; selection is automated. Report an issue

  1. Phase 3Non-small cell lung cancer (NSCLC)

    QL2107

    539 A randomized, double-blind, phase III trial to compare SB27 (a proposed biosimilar to pembrolizumab) to reference pembrolizumab in participants with metastatic non-squamous non-small cell lung cancer

    ORR at Week 24 was 34.6% in SB27 and 37.9% in Pembro; the ORR ratio was 0.89 and its 90% CI was (0.737, 1.071), which was within the pre-defined margin (FAS).

    Read the abstract (opens in a new tab)
  2. Phase 2Non-small cell lung cancer (NSCLC)

    nogapendekin alfa inbakicept

    496 Nogapendekin alfa inbakicept (NAI), an IL-15R agonist, prolongs OS in solid tumors after standard-of-care and checkpoint inhibitor (CPI) failure: updated results from QUILT-3.055

    Across all tumor types, mOS was 14.3 (95% CI: 12.2-16.9) and 15.8 versus 11.8 months in ALC responders (mean ALC ≥1,000 cells/µL) versus non-responders (hazard ratio [HR] 0.59; P = 0.0281).

    Read the abstract (opens in a new tab)
  3. Phase 2MelanomaIovance Biotherapeutics

    lifileucel

    335 Long-term durable efficacy of lifileucel one-time treatment: post-hoc landmark analysis of overall survival by response in advanced melanoma patients (C-144-01 study)

    Notably, 21 of 28 (75%) 5-year completers (7 CR, 11 PR, 3 SD) remained alive and treatment-free (no new anticancer therapy) with OS of 55.0 to 61.7 months after a single lifileucel infusion.

    Read the abstract (opens in a new tab)
  4. Phase 1/2Multiple myeloma (MM)

    IDP-023

    1185 IDP-023 allogeneic g-NK cells combined with isatuximab in relapse/refractory multiple myeloma: complete safety, efficacy, and tumor microenvironment remodeling from a Phase 1/2 first-in-human study

    Of 11 efficacy-evaluable IDP-023 + isatuximab patients, overall-response-rate (ORR) was 36% (4/11) and clinical-benefit-rate (CBR) 55% (6/11), versus 0%/3% expected for isatuximab alone in CD38-refractory disease.

    Read the abstract (opens in a new tab)
  5. Phase 1/2Colorectal cancer (CRC)

    MDNA11

    517 MDNA11 demonstrates clinical activity as monotherapy and in combination with pembrolizumab in biomarker-enriched gastrointestinal malignancies, including ICI-refractory disease

    MDNA11 plus pembrolizumab demonstrated an ORR of 57% (4/7; 95% CI: 18–90), including 1 unconfirmed response (lost to follow-up), and a DCR of 86% (6/7; 95% CI: 42–100).

    Read the abstract (opens in a new tab)
  6. Phase 1/2Cutaneous melanoma (CM)

    imneskibart

    611 Imneskibart + low-dose subcutaneous IL-2 ± nivolumab in doublet checkpoint inhibitor-refractory melanoma: promising activity in an ongoing phase 1/2 study

    Imneskibart + IL-2 was well tolerated with Grade 3/4 drug-related adverse events occurring in 14.5 % of pts and in 10.5% of pts who received the combination with nivolumab.

    Read the abstract (opens in a new tab)
  7. Phase 1Intraocular melanoma

    brenetafusp

    1177 Phase 1 evaluation of brenetafusp alone and in combination with tebentafusp in metastatic uveal melanoma

    Among 1L mUM patients (n = 17), tebentafusp + brenetafusp treatment was associated with favorable efficacy outcomes with 29% ORR, 24.1-month median DOR, 8.1-month median PFS, 88% 1-yr OS, and 70% 2-yr OS.

    Read the abstract (opens in a new tab)
  8. Phase 1Nonhematologic neoplasms

    an4005

    563 Updated safety and efficacy of AN4005, an oral small-molecule PD-L1 inhibitor, in advanced solid tumors: phase I dose-escalation and expansion

    Rash was more frequent in Part 3 than in Parts 1–2 (48% vs 2.9%) and had an early onset (median = 10 days), with most events manageable.ss In ASPS (Cohort 3A), ORR was 15% and the DCR was 60%; median duration of response was not reached.

    Read the abstract (opens in a new tab)
  9. Phase 1Enterocolitis

    SER-155

    534 High immunosuppressive-free response rate of immune checkpoint inhibitor (ICI)-related enterocolitis with SER-155, an investigational oral live biotherapeutic, in a phase 1b study

    Two participants (13%) experienced a serious TEAE, neither attributed to SER-155.

    Read the abstract (opens in a new tab)

What the abstracts covered

Share of the 647 drug-linked abstracts, by the target, modality, disease and company of each drug. An abstract can count in more than one row, so a list can add up to more than 100%.

  • Antibody-drug conjugates5%35 drug-linked abstracts · level with 4% in 2025
  • Bispecific antibodies13%87 drug-linked abstracts · level with 12% in 2025

Top targets

  1. PDCD18313% from 11% in 2025
  2. CD3467%
  3. CD274386% from 4% in 2025
  4. CD19284% from 6% in 2025
  5. IL2RB152%
  6. VEGFA152%
  7. CTLA-4142%
  8. B7-H3132%
  9. IL-12R132%
  10. CD28New122%

Top modalities

  1. Monoclonal antibodies18128% from 22% in 2025
  2. Small molecules15223% from 19% in 2025
  3. Cell therapies14623%
  4. Bispecific antibodies8713%
  5. Non-antibody therapeutic proteins7612% from 10% in 2025
  6. Oligonucleotide and RNA therapeutics376%
  7. Vaccines376% from 8% in 2025
  8. Gene therapies366%

Top diseases

  1. Melanoma12419%
  2. Colorectal cancer (CRC)8113%
  3. Non-small cell lung cancer (NSCLC)7011%
  4. Breast cancer498%
  5. Ovarian cancer376%
  6. Triple-negative breast cancer (TNBC)294%
  7. Glioblastoma (GBM)264%
  8. Pancreatic cancer (PC)254%
  9. Pancreatic adenocarcinoma (PDAC)244%
  10. Head and neck squamous cell carcinoma (HNSCC)234%

Most active companies

  1. Bristol Myers Squibb386%
  2. Merck335%
  3. AstraZeneca142%
  4. Genentech142%
  5. Amgen122%
  6. Novartis122%
  7. Iovance Biotherapeutics102%
  8. Pfizer102%
  9. Eli Lilly81%
  10. Johnson & Johnson71%

SITC over the years

  1. 20261,128 abstracts · this edition
  2. 20251,283 abstracts

Explore every SITC 2026 result in Gosset

All 647 drug-linked abstracts, joined to each drug’s trials, targets, developers and deals, with a source behind every line.

This page shows a sample of results. Gosset has the abstracts from this meeting and 100+ others; reach out for full access.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call